SV

Street Verdict

Analyst Scorecard

A record of what Choice Institutional Equities Analysis said publicly, with the source. Not advice.

“Choice Institutional Equities recommends buying Piramal Pharma with a target price of ₹315, based on a positive outlook for consumption-oriented sectors following the Union Budget 2025-2026, which balances fiscal prudence with economic stimulus and provides a boost to consumption.”

Choice Institutional Equities Analysis’s track record (trackable calls only): 77 graded calls · 95% CI 35–57%

Piramal PharmaBullishCalled 03 Feb 2025Graded 03 Feb 2026
Verdict:MISS

How this call is judged

A call is judged on closing prices only: a close at its target is a hit and a close at its stop is a miss. A call that states an entry starts at the first close that reaches it; if none does in the days allowed, it was never triggered, is not graded and counts toward no hit rate.

No entry price is stated, so the call starts at the first close after it was published.

Target ₹315, as stated.

Window: 12 months, the default when no time frame is stated.

Neither the target ₹315 was reached on a close by the end of the window. Miss.

The grader’s working: R4 TARGET_CALL: entered ₹227.02 on 2025-02-04 (next trading session's close); neither target nor stop reached by window end 2026-02-03. Window 365 days — rule H3: a target call whose quote states no time frame is given 12 months, the broker convention.

Tracking Piramal Pharma since this call

1-year tracking window
Read the original articleSee Choice Institutional Equities Analysis’s full track record